Research programme: cadherin antagonists - Adherex Technologies

Drug Profile

Research programme: cadherin antagonists - Adherex Technologies

Latest Information Update: 23 Feb 2011

Price : $50

At a glance

  • Originator McGill University
  • Developer Adherex Technologies
  • Class Organic chemicals; Peptides; Small molecules
  • Mechanism of Action Cadherin modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 25 Aug 2006 The programme is available for collaboration (http://www.adherex.com/)
  • 01 Apr 2005 This programme is still in active development
  • 20 May 2003 Preclinical trials in Cancer in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top